• 1
    Hewett JA, Roth RA. Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev 1993; 45: 382411.
  • 2
    Ganey PE, Roth RA. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 2001; 169: 195208.
  • 3
    Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy: is there a connection? J Pharmacol Exp Ther 2003; 307: 18.
  • 4
    Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, Descotes J. Side effects of ranitidine. Drug Saf 1991; 6: 94117.
  • 5
    Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003; 307: 916.
  • 6
    Hewett JA, Roth RA. The coagulation system, but not circulating fibrinogen, contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. J Pharmacol Exp Ther 1995; 272: 5362.
  • 7
    Hewett JA, Schultze AE, VanCise S, Roth RA. Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest 1992; 66: 347361.
  • 8
    Hewett JA, Jean PA, Kunkel SL, Roth RA. Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 1993; 265(6 Pt 1): G1011G1015.
  • 9
    Pearson JM, Schultze AE, Jean PA, Roth RA. Platelet participation in liver injury from gram-negative bacterial lipopolysaccharide in the rat. Shock 1995; 4: 178186.
  • 10
    Luyendyk JP, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, et al. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 2004; 80: 203213.
  • 11
    Colman R. Overview of hemostasis. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott, 1994: 3.
  • 12
    Copple BL, Banes A, Ganey PE, Roth RA. Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci 2002; 65: 309318.
  • 13
    Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998; 253: 743750.
  • 14
    Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995; 72: 889895.
  • 15
    Copple BL, Rondelli CM, Maddox JF, Hoglen NC, Ganey PE, Roth RA. Modes of cell death in rat liver after monocrotaline exposure. Toxicol Sci 2004; 77: 172182.
  • 16
    Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551578.
  • 17
    Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001; 15: 24452453.
  • 18
    Yee SB, Hanumegowda UM, Copple BL, Shibuya M, Ganey PE, Roth RA. Endothelial cell injury and coagulation system activation during synergistic hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure. Toxicol Sci 2003; 74: 203214.
  • 19
    Bini A, Itoh Y, Kudryk BJ, Nagase H. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry 1996; 35: 1305613063.
  • 20
    Luyendyk JP, Copple BL, Barton CC, Ganey PE, Roth RA. Augmentation of aflatoxin B1 hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. Toxicol Sci 2003; 72: 171181.
  • 21
    Horton MR, Olman MA, Bao C, White KE, Choi AM, Chin BY, et al. Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. Am J Physiol Lung Cell Mol Physiol 2000; 279: L707L715.
  • 22
    Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 5661.
  • 23
    Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-{alpha} and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-{kappa}B-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 2003; 307: 987994.
  • 24
    Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 13461353.
  • 25
    Montes R, Declerck PJ, Calvo A, Montes M, Hermida J, Munoz MC, et al. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost 2000; 84: 6570.
  • 26
    Abrahamsson T, Nerme V, Stromqvist M, Akerblom B, Legnehed A, Pettersson K, et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118126.
  • 27
    Savov JD, Brass DM, Berman KG, McElvania E, Schwartz DA. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol 2003; 285: L940L948.
  • 28
    Fujiwara K, Ogata I, Ohta Y, Hirata K, Oka Y, Yamada S, et al. Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut 1988; 29: 11031108.
  • 29
    Copple BL, Woolley B, Banes A, Ganey PE, Roth RA. Anticoagulants prevent monocrotaline-induced hepatic parenchymal cell injury but not endothelial cell injury in the rat. Toxicol Appl Pharmacol 2002; 180: 186196.
  • 30
    Yee SB, Harkema JR, Ganey PE, Roth RA. The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci 2003; 74: 457469.
  • 31
    Kinser S, Copple BL, Roth RA, Ganey PE. Enhancement of allyl alcohol hepatotoxicity by endotoxin requires extrahepatic factors. Toxicol Sci 2002; 69: 470481.
  • 32
    Pearson JM, Schultze AE, Schwartz KA, Scott MA, Davis JM, Roth RA. The thrombin inhibitor, hirudin, attenuates lipopolysaccharide-induced liver injury in the rat. J Pharmacol Exp Ther 1996; 278: 378383.
  • 33
    Copple BL, Ganey PE, Roth RA. Hypoxia in rat liver after monocrotaline exposure [Abstract]. Toxicol Sci 2004; 78(S-1): 491.
  • 34
    Marotto ME, Thurman RG, Lemasters JJ. Early midzonal cell death during low-flow hypoxia in the isolated, perfused rat liver: protection by allopurinol. HEPATOLOGY 1988; 8: 585590.
  • 35
    Lemasters JJ, Ji S, Thurman RG. Centrilobular injury following hypoxia in isolated, perfused rat liver. Science 1981; 213: 661663.
  • 36
    Shibayama Y. Enhanced hepatotoxicity of endotoxin by hypoxia. Pathol Res Pract 1987; 182: 390395.
  • 37
    Stadnicki A. Ranitidine and haemostasis in man. Hepatogastroenterology 1984; 31: 230232.
  • 38
    Valois M, Cooper MA, Shear NH. Clinical pharmacology consultations: consultation requests may be misleading—an organized approach to drug-induced hepatitis. Can J Clin Pharmacol 2003; 10: 5962.
  • 39
    Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 15171532.
  • 40
    Lind RC, Gandolfi AJ, Sipes IG, Brown BRJ. The involvement of endotoxin in halothane-associated liver injury. Anesthesiology 1984; 61: 544550.
  • 41
    Ulrich RG, Bacon JA, Brass EP, Cramer CT, Petrella DK, Sun EL. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chemico-Biol Interact 2001; 134: 251270.
  • 42
    Bacon JA, Cramer CT, Petrella DK, Sun EL, Ulrich RG. Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Toxicology 1996; 108: 916.